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            Abstract 
Children with chronic illness, on average, have low rates of adherence to their 
medical regimens despite the possible medical and psychological consequences. 
Many different interventions have been developed to increase adherence in this 
population, and the results are mixed. Some studies show strong results, while others 
only slightly increase adherence. The purpose of this meta-analysis was provide 
quantitative information about the overall effectiveness of adherence interventions for 
children with a chronic illness, as well as statistically evaluate potential moderators of 
the effectiveness of interventions (e.g., behavioral vs. educational interventions, age 
of child). Overall, adherence interventions for children with chronic illnesses appear 
to effectively increase adherence and maintain benefits at follow-up. Additionally, 
these adherence interventions overall appear to have some positive health benefits. 
Some intervention and methodological variables, such as study design and assessment 
method, had a significant effect on effect sizes. However, most of the data included in 
this meta-analysis should be interpreted with caution because of high levels of 
heterogeneity within the data. This suggests that more targeted summaries of the 
research (i.e., adolescents with asthma) would provide more useful information about 
the effectiveness of adherence interventions. 
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 The Efficacy of Adherence Interventions for Chronically Ill Children: 
A Meta-analytic Review 
Introduction 
 Low adherence to medical regimens is common among children with a 
chronic illness. On average, children take about 50% of the medication prescribed for 
their chronic illness (Drotar, 2000; Rapoff & Barnard, 1991). This low rate has 
persisted despite the development of more effective medications, increased attention 
to provider-patient communication, more available patient education, and greater 
awareness of adherence issues. The significance of this relatively low level of 
adherence is particularly salient when considering the evidence of harm due to 
nonadherence. The body of scientific knowledge about adherence is increasing, and 
adherence interventions are continually being designed and tested. As the evidence 
accumulates, it is important to evaluate the adherence intervention literature to better 
understand which techniques work best. By doing so, resources can be focused on the 
most effective interventions to tackle the complex problem of adherence.  
 Adherence has been defined as “the extent to which a person’s behavior 
coincides with medical or health care advice” (Haynes, 1979, pp. 1-2). This definition 
is useful because it highlights the fact that adherence is a continuum (Rapoff, 1999). 
For example, few patients take all or none of their medications. Using the term 
adherence rather than compliance also emphasizes that the patient takes an active role 
in medical decisions, rather than passively agreeing to the provider’s orders (Rapoff, 
1999). Additionally, nonadherent patients may be making reasoned decisions about 
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 their medical care (Adams, Dreyer, Dinakar, & Portnoy, 2004). For example, patients 
may choose to experience more symptoms in order to take less medication (Heath, 
Singer, O'Shaughnessy, Montaner, & Hogg, 2002). This decision can appear rational 
when considering the possible long term or dangerous side-effects of some 
medications. 
 Despite the fact that choosing to be nonadherent is sometimes understandable 
and rational, nonadherence has been linked to many negative health effects. In 
pediatric asthma, adherence rates vary from 50% to 80% (Bender et al., 2000). 
Nonadherence to asthma medications has been linked to increased rates of emergency 
room visits, hospitalization, and missed school days (Bauman et al., 2002). Increasing 
evidence also suggests that nonadherence to inhaled corticosteroids (prescribed to 
reduce inflammation in the lungs) can lead to permanent airway restructuring or 
scarring of the lungs (Pascual & Peters, 2005). For children with diabetes, 
nonadherence to insulin delivery and blood glucose monitoring can lead to poor 
glycemic control, with short term consequences of weight loss, poor concentration, or 
diabetic ketoacidosis and long term consequences of diabetes related kidney, eye, and 
skin complications (Johnson et al., 1992; Sochett & Daneman, 1999). Nonadherent 
children with organ transplants (rates of 6 to 9%) are at a great risk of losing their 
organ graft (Falkenstein, Flynn, Kirkpatrick, Casa-Melley, & Dunn, 2004; Serrano-
Ikkos, Lask, Whitehead, & Eisler, 1998). Children with juvenile rheumatoid arthritis 
(JRA) who are nonadherent to nonsteroidal anti-inflammatory medicines 
(nonadherence rates of about 50%) are likely to have more pain episodes that 
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 interfere with quality of life and may also cause permanent damage to their joints 
(Rapoff, Belmont, Lindsley, & Olson, 2005). In short, nonadherence to medications 
for pediatric chronic illnesses can be linked to many health complications, as well as 
reductions in quality of life. In fact, nonadherence to medications, including adult and 
child populations, was estimated to cost at least $100 billion annually in the United 
States (Berg, Dischler, Wagner, Raia, & Palmer-Shevlin, 1993). 
 Because of the many possible negative effects of nonadherence, there is a 
strong interest in developing interventions to increase adherence. In general, 
adherence intervention strategies are divided into three groups: behavioral, 
educational, and organizational (La Greca & Schuman, 1995). Many treatments 
combine two or more of these techniques. Other strategies include addressing 
psychological issues that may interfere with adherence, such as family systems 
problems, depression, or general child noncompliance (i.e., refusal to follow most of 
parent’s directions).  
Behavioral Interventions 
 Behavioral interventions use techniques such as modifying the environment to 
encourage adherence, shaping adherent behaviors, and providing positive and 
negative consequences for adherence. Often these techniques are taught to parents to 
implement at home. For example, da Costa and colleagues taught families to 
implement a token system wherein the child could earn or lose privileges based on 
having taken his or her asthma medication (da Costa, Rapoff, Lemanek, & Goldstein, 
1997). Researchers sometimes assist parents in implementing these techniques during 
3 
 home visits. In one such project, nurses went to the homes of children with human 
immunodeficiency virus (HIV) and provided HIV education as well as behavioral 
components such as teaching parents how to better organize and remember the child’s 
medications (i.e., using weekly medication boxes) and providing rewards to children 
for taking their medications (Berrien, Salazar, Reynolds, & McKay, 2004). 
Additionally, some researchers have evaluated the use of behavioral techniques in 
office sessions. For example, Anderson, Ruggiero, and Adams (2000) report using 
shaping and rewards (i.e., parental attention, cookies, and stickers) to teach a young 
boy with HIV how to swallow pills, because the boy’s fear of pill swallowing was the 
major impediment to adherence for that family. Each of these studies reported that the 
interventions resulted in improved adherence.  
Educational Interventions 
 Prompted by evidence that nonadherence can be the result of a family not 
understanding the physician’s orders, the purpose of the medical regimen, or how to 
use medical equipment, educational interventions seek to provide education to the 
family on these and other relevant topics. Educational interventions can range from 
handouts given by nurses at the end of clinic visits to intensive home-based teaching 
programs. In one published intervention, children with diabetes were given video 
games, which were designed to teach the importance of adherence to diabetes self-
management tasks (Brown, Lieberman, Gemeny, Fan, Wilson, & Pasta, 1997). In 
another example of an educational intervention, general practitioners used an asthma 
information book and structured education sessions to teach parents of preschool 
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 children about appropriate asthma medication use (Mesters, van Nunen, Crebolder, & 
Meertens, 1995). In both studies, the researchers reported a significant decline in 
unscheduled urgent doctor visits and an increase in self-reported appropriate 
medication use.  
Organizational Interventions 
 Organizational strategies seek to reduce nonadherence by decreasing barriers 
to medical care and medication use. Some specific techniques include helping 
families find transportation to doctor appointments, teaching good communication 
skills to medical staff, and reducing the complexity and negative side-effects of the 
medical regimen (Rapoff, 1999). In general, fewer studies are published highlighting 
these types of interventions. However, at least two studies have shown that by 
reducing the frequency of medication dosing, adherence is improved in children with 
asthma (Tinkelman, Vanderpool, Carroll, Page, & Spangler, 1980) and children with 
JRA (Rapoff, Purviance, & Lindsley, 1988a).  
Measurement of Adherence 
 In examining the many methods, modalities, and structures of adherence 
interventions for children with a chronic illness, the most important evaluative 
question is whether or not the intervention successfully reduces nonadherence. 
However, before change in adherence levels can be determined, experimenters must 
develop ways to assess treatment regimen behaviors. One of the simplest and quickest 
ways to assess treatment adherence rates is to obtain the self-report of the parent and 
child. However, self-report is generally considered an overestimate of adherence 
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 behavior, because it is influenced by recall errors and social desirability (Quittner, 
Espelage, Ievers-Landis, & Drotar, 2000). Another easy, but perhaps more direct 
measure, of adherence is pill counts, wherein the researcher counts the number of 
pills left in a medicine bottle and compares it to the number of pills that should be left 
if the patient was completely adherent. However, this is an inexact measurement 
system, as there is no way to discern if the pills were taken on the correct schedule or 
if the pills were “dumped” by the patient in anticipation of the pill count (Rapoff, 
1999). Blood assays of medication levels are considered good indicators of recent 
medication use, but can only be used with certain medications and are expensive 
(Rapoff, 1999). Electronic monitoring is generally considered to provide the most 
informative and accurate data (Vrijens & Urquhart, 2005). By using electronic 
monitors on pill bottles, inhalers, or other medical devices, researchers can determine 
the time and date of medication use. The drawbacks of this technique include the 
expense of the monitors, the possibility that being monitored will change medication 
taking rates, inability to detect medication consumption on most models, and the 
limited availability of devices to measure all types of adherence (Vitolins, Rand, 
Rapp, Ribisl, & Sevick, 2000). Thus, researchers have many options when it comes to 
measuring adherence. In order to balance the strengths and weaknesses of each 
method, researchers have been encouraged to use multiple techniques (Modi, Lim, 
Yu, Geller, Wagner, & Quittner, 2006).  
 Adherence intervention researchers sometimes use physiological or health 
outcomes, such as lung functioning in children with asthma, as an indicator of 
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 appropriate medication use. However, adherence does not necessarily have a direct 
relationship with changes in health status (DiMatteo, Giordani, Lepper, & Croghan, 
2002; Johnson et al., 1992). Thus, health outcomes are often seen as secondary 
outcomes of interventions. Other secondary outcomes sometimes measured are 
quality of life, health care utilization and costs, and functional impact of the chronic 
illness (e.g., school days missed). Although these secondary outcomes may not be 
directly related to increasing adherence, considering changes in these domains is 
important in understanding the full effect of an intervention (La Greca & Bearman, 
2001). 
Intervention Outcome Research 
 In general, the consensus in the literature is that effective interventions are 
available for increasing adherence to the treatment regimens for childhood chronic 
illnesses. Lemanek, Kamps, and Chung (2001) evaluated adherence interventions 
using the Chambless empirically-supported treatment criteria (Task Force, 1995). 
They concluded that behavioral interventions are “probably efficacious” for some 
medical regimen components (e.g., taking doses of a medication). Additionally, 
education, self-monitoring, and combination interventions are “promising,” 
particularly when the intervention can be adapted to meet the individual’s specific 
needs. However, the Lemanek et al. review covered only adherence interventions for 
three conditions (i.e., asthma, JRA, and type-1 diabetes). Rapoff (1999) made similar 
conclusions after a systematic literature review. Specifically, he stated that behavioral 
interventions appear to have the most empirical support. Additionally, although 
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 educational and organizational techniques may be useful, these interventions are 
likely more efficacious when combined with behavioral techniques.  
Although both of these reviews provide good summaries of the existing 
literature, the overall quantitative power and effectiveness of adherence interventions 
cannot be determined from these and other reviews. A meta-analysis is the best 
technique to provide that information (Rosenthal, 1995). Several meta-analytic 
reviews have been published on adherence interventions for adults. Most of these are 
disease specific (e.g., HIV: Amico, Harman, & Johnson, 2006; hypertension: Takiya, 
Peterson, & Finley, 2004), but at least two published studies have examined the 
relative effectiveness of adherence interventions across many patient conditions and 
adherence measures (Peterson, Takiya, & Finley, 2003; Roter, Hall, Merisca, 
Nordstrom, Cretin, & Svarstad, 1998). The Peterson et al. (2003) meta-analysis 
concluded that effects of adherence interventions were generally small, despite 
intensive and complex interventions. In contrast, the Roter et al. (1998) meta-analysis 
indicated that, for the studies included, the overall effect sizes for increased adherence 
ranged from small to large. Roter and colleagues also concluded that combined-type 
interventions (e.g., educational and behavioral) were more effective than single-type 
interventions. This difference in conclusions may be because Roter et al. (1998) 
included both randomized and nonrandomized studies, where as Peterson et al. (2003) 
only included randomized clinical trials. Both meta-analyses had notable limitations. 
First, both combined acute and chronic illnesses, and the Peterson et al. (2003) meta-
analysis also included psychiatric illnesses. Combining acute and chronic illnesses is 
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 problematic since the medication regimens for chronic illness have different barriers 
for adherence than acute illness medications (Rapoff, 1999). In fact, a meta-analysis 
conducted with only acutely ill children reached some similar conclusions (i.e., 
combined-type interventions are more effective than single-type) but also had some 
significantly different results (e.g., the interventions did not have a significant 
positive effect on health outcomes), suggesting that there are some important 
differences between adherence interventions for chronically ill children and acutely ill 
children (Wu & Roberts, 2008) Additionally, both meta-analyses combined studies 
targeting children and adults. Because interventions for children include aspects not 
necessary in adult interventions, such as parental involvement and developmentally 
appropriate education, adult-based research should not be assumed to provide similar 
results as child-based research. Thus, a meta-analysis that focuses only on chronically 
ill children will provide more accurate results by reducing some of the extra variance 
that is created by combining disparate groups.  
Only one meta-analysis was found in the literature that focused specifically on 
adherence interventions for children with chronic illnesses. Analyzing 70 studies, 
Kahana, Drotar, and Frazier (2008) concluded that the mean effect size of all the 
included adherence outcomes was in the small range. Similar to conclusions from 
literature reviews, they found that behavioral and multi-component interventions had 
stronger effects (medium range) than those interventions that just used educational 
techniques (small range). There were some limitations in this meta-analysis. For 
example, most single subject design studies were excluded from this meta-analysis, 
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 even though these studies are important in adherence intervention research because of 
their utility for studying chronic illness groups that are relatively rare and for 
providing interventions that are uniquely matched to a family’s individual needs 
(Rapoff, 2001). The Kahana et al. (2008) meta-analysis also did not include any data 
about health outcome results from the interventions, although improved health 
outcomes is an important goal of adherence interventions. Perhaps the most striking 
drawback is that most of the summary adherence data presented in this meta-analysis 
had high levels of heterogeneity, meaning that the variance between the combined 
effect sizes was significantly more than expected based on chance and sampling error. 
In other words, the effect sizes likely did not represent a singular construct. In fact, a 
mean effect size with significant heterogeneity should only be interpreted with 
caution (Durlak, 2003). Although the authors attempted to understand the 
heterogeneity by examining moderators, the problem with heterogeneity was not fully 
addressed by Kahana et al. (2008) when interpreting the implications of their data. 
The current meta-analysis provides an expanded view of the adherence 
intervention research by including more single-subject design studies and health 
outcome data. Additionally, since there is no consensus in the research community on 
the best procedures for all steps of a meta-analysis, slightly different decisions were 
made for this meta-analysis than those made for the Kahana et al. (2008) meta-
analysis. In fact, of the studies included in this meta-analysis, only 19 out of 71 were 
also in the Kahana et al. (2008) meta-analysis. The reason for this significant 
difference in studies sampled is unclear but is most likely due to differences in 
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 inclusion criteria. For example, Bonner et al. (2002) was included in the Kahana et al. 
(2008) meta-analysis, but excluded from this one because it was considered a self-
management intervention (see exclusion criteria below). These procedural differences 
do not represent significant flaws in either study, but rather provide slightly different 
representations of the adherence intervention literature. Additionally, these 
differences could affect some of the statistical results. Thus, having more than one 
meta-analysis on the effectiveness of adherence interventions for chronically ill 
children deepens the understanding of this research area. For example, in the adult 
literature, the Roter et al. (1998) and Peterson et al. (2003) studies sampled different 
types of adherence intervention studies (i.e., only the Peterson et al. study included 
adherence to psychiatric medications). Thus, taken together these two studies cover a 
wider range of adherence intervention research and allow for more complex 
conclusions. 
In summary, the present meta-analysis attempted to provide a quantitative 
summary of the research on adherence interventions for children with chronic 
illnesses. Additionally, this meta-analysis evaluated the influence of different 
intervention methods, assessment types, methodological variables, and participant 
characteristics on study effect sizes. Health outcome and follow-up data were also 
analyzed.  
11 
 Method 
Literature Search 
 Computerized and manual methods were used to identify studies to be 
included in this meta-analysis. The computer searches were conducted using PubMed 
(an enhanced version of MEDLINE) and PsycINFO, which includes psychology 
dissertation abstracts. The searches included all years included in the databases up to 
November 2006. For each database, a total of thirty-six searches were completed. In 
the first set of eighteen searches, the keyword “adherence” was paired with each of 
the following second keywords: “treatment,” “strategies,” “improve,” “interventions,” 
“education,” and “medication.”  Each of these pairs was combined with the following 
third keywords: “child,” “adolescent,” and “pediatric.”  For the second set of eighteen 
searches, the word “compliance” was substituted for “adherence.”  This created a 2 x 
6 x 3 search pattern. Additionally, a manual search was conducted of the 1990 to 
2006 issues of journals which were expected to contain the most adherence 
intervention studies (i.e., Journal of Pediatric Psychology, Pediatrics, and Children’s 
Health Care). The starting date of 1990 was selected because the majority of 
adherence intervention studies have been published in the last fifteen years (Peterson 
et al., 2003). Manual searches were also conducted using the reference section of 
Rapoff’s literature review (1999), as well as other reviews (e.g., Lemanek et al., 
2001). Solicitation letters were sent to the primary authors of studies to request 
additional data when effect sizes could not be calculated from published results. Only 
12 
 studies or abstracts written in English were retained for review, because translation of 
non-English articles would have been prohibitively expensive and time consuming.  
A total of 340 studies were collected using this search process. Of these 
studies, eighteen were dissertations. Dissertations were included in the literature 
review for several reasons. First, it is important for unpublished research to be 
included because of the possibility of publication bias, which is the tendency for 
authors not to submit and editors not to accept nonsignificant findings (Durlak, 2003). 
In fact, Lipsey and Wilson (1993) statistically proved the existence of this 
phenomenon in their large meta-analysis on psychological treatments by 
demonstrating that unpublished studies had similar but overall slightly lower effect 
sizes than published studies. Thus the inclusion of unpublished studies provides a 
better estimate of the true mean effect. The potential for publication bias can also be 
determined by comparing the effect sizes of these unpublished studies to those of the 
published studies, such that significant differences would suggest the possibility of a 
problematic publication bias (Greenhouse & Iyengar, 1994). Dissertations, compared 
to unpublished conference proceedings, can be considered to have been rigorously 
reviewed by a group of experts, similar to the peer-review system of journal articles. 
Additionally, the Dissertation Abstract International database facilitates a thorough 
search of this population of studies, whereas nothing similar exists for other areas of 
unpublished research. 
Inclusion and Exclusion Criteria 
 To be included in the meta-analysis, a study had to meet the following criteria: 
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 1. The study participants were diagnosed with a chronic illness. The 
following definition of chronic illness has been adopted by the World 
Health Organization (Sabaté, 2001) and was also used for this study: 
chronic illnesses “have one or more of the following characteristics: they 
are permanent, leave residual disability, are caused by nonreversible 
pathological alteration, require special training of the patient for 
rehabilitation, or may be expected to require a long period of supervision, 
observation or care” (Timmreck, 1982, p. 102). If the designation of an 
illness was in question (i.e., infectious, acute, or chronic), the Center for 
Disease Control and Prevention’s website (www.cdc.gov) was consulted 
for their classification of the illness. This technique was used to exclude 
malaria, tuberculosis, and amblyopia. 
2. The study was a treatment or intervention that used a systematic attempt to 
alter specific behaviors related to carrying out medical regimens. Medical 
regimens could include taking medications, following diets, and doing 
prescribed exercises. Adherence must be one of the primary aims of the 
study, not a secondary product of a self-management intervention. Self-
management programs “attempt to provide individuals with chronic 
conditions the knowledge, skills, and self-efficacy necessary to take an 
active role in the management of their medical condition” by teaching or 
encouraging “self-monitoring, medication compliance, environmental 
14 
 control, relaxation, and problem solving” (Meade, Creer, & Mahan, 2003, 
p. 165). 
3. The study quantitatively measured adherence, so that the statistical effect 
of the intervention on adherence could be determined. For example, if 
health outcome data were included (i.e., emergency room visits, A1C 
results for diabetes), but there were no data about whether the medication 
was taken appropriately, then the study was not included. 
4. The study sought to increase adherence in children, which was defined as 
people under the age of 21 years old. If the study included both children 
and adults, it had to provide separate data for the children to be included.  
As mentioned previously, the initial literature search identified 340 potential 
studies for inclusion. All but 71 of these studies were excluded. Studies were 
excluded for the following reasons: self-management interventions (n = 52), not 
chronic illness (n = 50), inadequate data (n = 49), not an adherence intervention (n = 
43), included adults (n = 28), correlational study (n = 21), review articles (n = 18), 
and data reported in another publication (i.e., dissertation data excluded because 
published later in a peer-reviewed journal; n = 8).  
Coding 
Two independent raters were trained to code information about study sample 
size and characteristics, study methodology, intervention types, outcome measures, 
and the statistics needed to compute effect sizes. One of these raters was the author of 
this meta-analysis (MG), and the other rater was a trained research assistant. Using 
15 
 methods recommended by Stock (1994), ten studies were used to refine the coding 
system and train the raters. Discrepancies in the coding were resolved by discussing 
the criteria and refining them if necessary. For the couple of occasions that a 
discussion between the two raters was not adequate in resolving the uncertainty, 
Michael Rapoff, Ph.D., an expert in the field of adherence interventions, was 
consulted. Interrater reliability was determined by having both raters code 20% of the 
included studies. Kappa was calculated as a measure of agreement for categorical 
data and ranged from .96 to 1.0, with a mean kappa of .99, indicating a high level of 
rater agreement (Orwin, 1994). Intercoder correlation was used for continuous 
variables and ranged from .80 to 1.0, with a mean r2 of .95, indicating a high level of 
rater agreement. See Appendix A for the coding form. 
Intervention-Related Variables. The interventions were divided into four 
categories: (a) educational, (b) behavioral, (c) organizational, (d) psychological/other, 
(e) educational and behavioral, and (f) all other combinations. An intervention was 
coded as “educational” if information or teaching was provided about the chronic 
illness or medical regimen. “Behavioral” interventions used techniques to encourage 
adherence, shape adherent behaviors, or provide positive and negative consequences 
for adherence. “Organizational” interventions were those that used techniques the 
health care provider could implement to reduce barriers to adherence, such as 
reducing the complexity of the regimen. The “psychological/other” category included 
interventions for psychological diagnoses (e.g., depression) and family therapy that 
16 
 was not primarily focused on the medical regimen, but were hypothesized to increase 
adherence. 
Outcome-Related Variables. Outcome measures were coded into three 
categories: (a) direct measures, (b) indirect measures, and (c) subjective measures. 
The only direct measure of adherence included was blood or urine tests that indicated 
medication levels in the child. Indirect measures were those that measured regimen 
adherence in an objective way, including electronic medication monitors and pill 
counts. Subjective measures included self-report measures, medication use record 
keeping, and 24 hour recall. Health outcome data were also collected. Examples of 
health outcomes included pain ratings, functional disability, lung function tests, and 
health care utilization. 
Methodology-Related Variables. Methodological variables were coded for two 
purposes. First, the quality of the reviewed literature is important to consider when 
making conclusions about the strength of the meta-analysis. Second, methodological 
features may be important moderators of the adherence outcomes (Durlak, 2003). The 
methodological variables that were coded for the purpose of this meta-analysis 
include type of publication (e.g., journal article, dissertation), treatment attrition rates, 
length of the treatment, type of research design (e.g., randomized control trial, within-
subject, single subject), and nature of the control group (e.g., treatment as usual, 
alternative treatment). 
Possible Moderator Variables. In order to include other variables that may 
influence outcomes, some variables were coded because of their potential as 
17 
 moderators. These variables were chosen because previous research in adherence 
suggests that they may affect adherence rates and the efficacy of adherence 
interventions. These variables included the age, gender, ethnicity, and socioeconomic 
status of the participating children. 
Effect Size Estimates 
 Because the outcome variables for this meta-analysis were inherently 
continuous and each study used different measures or scales, the recommended effect 
size (ES) estimate for this meta-analysis is the standardized mean difference effect 
size (Lipsey & Wilson, 2001). This ES, also known as the d statistic ES, was derived 
by dividing the difference between two groups (e.g., pre-post or treatment-control) by 
the pooled standard deviation. (See Appendix B for this equation and others used in 
this meta-analysis.) Lipsey and Wilson (2001) provided multiple equations which 
were used to derive the standardized mean difference ES from various types of 
outcome statistics that were reported by studies, including F-tests, t-tests, and 
correlations.  
 For small sample sizes, the standardized mean difference ES has been found 
to be upwardly biased, particularly for sample sizes under 20. Hedges (1981) 
developed a simple correction for this bias. Thus, for all studies in this meta-analysis 
that had samples sizes less than 20, this correction was used. Additionally, studies 
with larger sample sizes are considered to be a more precise reflection of the 
population ES. Thus, in order to weight for sample size, Durlak (2003) recommended 
weighting each ES by the inverse of its variance, using an equation derived by 
18 
 Hedges and Olkin (1985). All of the ESs used in this meta-analysis were reported in 
weighted form. 
 Maintaining Independence. Independence within datasets is necessary for 
most statistical methods and also for maintaining the integrity of the conclusions 
drawn from a meta-analysis. Several steps were taken to maintain independence. 
First, if multiple articles were published using the same participants, these articles 
were combined and considered as one study. Second, the problem of multiple 
endpoints per study was considered. For example, many adherence interventions 
report several different types of outcome, such as self-report, electronic monitoring, 
and functional disability. In general, there are three ways to handle this situation (a) 
using generalized least squares approaches (see Gleser & Olkin, 1994), (b) selecting 
one of the effect sizes to represent each study, and (c) computing an average effect 
size for each study (Faith, Allison, & Gorman, 1996).  
 Although the generalized least squares approach accounts for the most within-
study correlation and variance, this approach requires data that are not available for 
the adherence literature (e.g., the actual variance between two outcome measures). 
Additionally, this method is most robust when the studies all use the same treatments 
and outcome measures (Gleser & Olkin, 1994). Selecting an effect size to represent 
each study is potentially problematic because neither research nor expert consensus 
has concluded that one form of adherence outcome is a better reflection of true 
adherence than any other outcome measure. Additionally, the preferred method of 
measuring adherence outcomes differs depending on the chronic illness group, the 
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 medication regimen, and the intervention type (Quittner et al., 2000). Thus, for the 
purpose of this meta-analysis, effect sizes were averaged within studies or within the 
subgroup being reported (i.e., the subjective measure effects). 
 Single-case Studies. Because single-subject designs are used in adherence 
intervention research to study relatively rare chronic illness groups and individualized 
or targeted interventions (Rapoff, 2001), single-case studies were included in this 
meta-analysis. For those studies that did not provide sufficient statistics for 
calculating effect size (e.g., means and standard deviations), measurements were 
taken from graphs to use as individual data points. Specifically, a ruler was used to 
measure the distance between each data point and the x-axis of the graph (Faith et al., 
1996). Effect sizes were calculated by finding the difference between the baseline 
mean scores and treatment mean scores. When assuming equality of variance across 
baseline and treatment phase, this difference is divided by the pooled within-phase 
standard deviations (Busk & Serlin, 1992). This technique was used for this meta-
analysis both because of its accepted validity and because it provides a statistic that 
can be compared with the other effect sizes obtained in this meta-analysis. However, 
even though all of the effect sizes used the same metric (d), group studies were not 
combined with single-case studies. This procedure was used because the two research 
designs provide fundamentally different estimates (i.e., within-person variation vs. 
averaged change data; Faith et al., 1996). 
 Two statistical models can be used to combine and summarize effect sizes: 
fixed-effects or random-effects. According to Hedges and Vevea (1998), the model 
20 
 should be chosen based on the type of inference desired. Specifically, fixed-effects 
models only contain within-group sampling error estimates and thus, can only provide 
information about the studies included in the meta-analysis. On the other hand, 
random-effects models include both within-group sampling error and between-study 
error measurements. In other words, random-effects assume that the studies included 
in the meta-analysis are a random sample of all possible studies, and that the results 
of the meta-analysis can be generalized to other studies similar to those included in 
the analyses. Thus, the random-effects model was used in this meta-analysis 
whenever combining the results of multiple studies.  
Homogeneity Testing 
 Homogeneity tests, using the Q statistic, were used to determine whether all of 
the effect sizes reflected the same population. In other words, the Q statistic 
established whether it is appropriate to group all of the studies into one analysis based 
on the assumption that they all estimate the same effect (Durlak, 2003). The Q 
statistic assesses whether the variability in the effect sizes is greater than expected 
based on chance and sampling error. This statistic is distributed as a chi square 
variable with degrees of freedom (df) equal to the number of studies minus one 
(Lipsey & Wilson, 2001). A nonsignificant Q-value indicates homogeneity.  
 The Q statistic can also be used to perform a statistical test which is analogous 
to an analysis of variance (ANOVA; Lipsey & Wilson, 2001). For this test, Q 
statistics are calculated for separate groupings of effect sizes (e.g., asthma and 
diabetes). Next, similar to ANOVAs, the within group homogeneity is compared to 
21 
 the between group homogeneity. If the resulting Q statistic is nonsignificant, then the 
effect sizes for the two groups are significantly different. 
Interpreting the Results 
 Two techniques were used to interpret the significance of the effect sizes. 
First, since the effect sizes used are d statistics, the generally accepted criteria for 
small (.20), medium (.50), and large (.80) effects were used (Cohen, 1988). These 
criteria have been empirically confirmed by Lipsey and Wilson (1993). Second, 95% 
confidence intervals (CI) were calculated for each group of effect sizes. If a CI 
included zero, then the effect size was considered not statistically significant. 
Results 
Description of Studies 
Study Design Characteristics. Of the 71 included studies, 34 (48.6%) used a 
comparison group design (i.e., experimental versus control group), 17 (24.3%) used a 
within subject design (i.e., pre-post studies), and 19 (27.1%) used a single-subject 
design. Of the comparison group studies, the control group was assigned an 
alternative treatment in 11 studies (32.4%), treatment as usual in 20 studies (58.8%), 
and waitlist in 3 studies (8.8%). Because the single-subject design studies were 
analyzed separately from the other studies, the remainder of the study descriptions 
provides separate data for the single subject studies. Of the non-single-subject design 
studies (n = 51), 16 studies involved asthma (31.4%), 15 with type 1 diabetes 
(29.4%), 5 with CF (9.8%), 3 each with HIV/ AIDS or post-transplant (5.9%), 2 each 
with hyperlipidemia, JRA, and sickle cell disease (3.9% each), and one each with 
22 
 epilepsy, hemophilia, and phenylketonuria (2.0% each). The percentage of attrition 
from the beginning of the study to the end of treatment was reported by 36 studies 
(70.6% of the studies), and attrition rates ranged from 0% to 49% (M = 13.3, SD = 
12.8). Of the single-subject design studies (n = 19), 7 studies involved type 1 diabetes 
(36.8%), 3 each with JRA and CF (15.8% each), 2 with asthma (10.5%), and one each 
with epilepsy, lung disease, various rheumatic diseases, and sickle cell (5.3% each). 
See Tables 1 and 2 for a description of all included studies. 
 Nine (12.7%) of the included studies were dissertations. The dissertations had 
a weighted mean effect size of 0.49, with a 95% confidence interval of 0.26 - 0.72. 
The remaining published studies had a weighted mean effect size of 0.57, with a 95% 
confidence interval of 0.49 - 0.63. Although the dissertations had a slightly smaller 
mean effect size, both effect sizes are considered in the medium range. Additionally, 
the confidence intervals overlap considerably, suggesting that the dissertations do not 
represent a significantly different population of studies than the published studies. 
Thus, they were included in all subsequent analyses. 
 Demographic Characteristics. The mean age of the youth included in each 
study ranged from 2 to 15 years (M = 9.9, SD = 3.7). Thirty-eight studies provided 
information about the participating children’s gender. The percentage of males ranged 
from 24% to 91% (M = 51.7, SD = 14.2). Only 22 studies (43%) reported quantifiable 
information about the ethnicity of the participants. Of these studies, the percentage of 
minority group participants ranged from 0% to 100% (M = 39.1, SD = 31.4). Fifteen 
studies (29.4%) reported the average time since diagnosis of a chronic illness for the 
23 
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 children in the study. Time since diagnosis ranged from 4 to 125 months (M = 53.0, 
SD = 33.4). Eighteen studies (35.3%) provided information about socioeconomic 
status (SES) of the included samples, but SES was based on a wide range of indices 
(e.g., Hollingshead index, parental income, etc.). Because so few studies provided 
SES information and the information was so varied, these data were not aggregated or 
used in any analyses. 
 Demographic Characteristics – Single Subject. The mean age of the youth 
included in each single subject study ranged from 2 to 17 years (M = 11.0, SD = 4.3). 
All of the studies provided information about the participants’ gender. The percentage 
of males ranged from 0% to 100% (M = 47.1, SD = 44.1). Only 4 studies (21%) 
reported information about the ethnicity of the participants. Two studies had 0% 
minority participants and two studies had 100% minority participants. Seven studies 
(36.8%) reported the average time since diagnosis of a chronic illness for the children 
in the study. Time since diagnosis ranged from 7 to 96 months (M = 48.3, SD = 32.1). 
None of the studies provided information about the socioeconomic status (SES) of the 
included samples.  
 Intervention Characteristics. Almost half of the studies utilized a combined 
educational and behavioral treatment techniques (n = 24, 47.0%). About one fourth 
utilized a single approach: organizational (n = 6, 11.8%), behavioral (n = 5, 9.8%), 
and educational (n = 2, 3.9%). The remainder of the studies (n = 13, 25.4%) used a 
variety of combinations (i.e., organizational and educational, psychological and 
31 
 educational, etc.). The length of the treatments ranged from 1 to 1095 days (M = 
167.5, SD = 109). 
Intervention Characteristics – Single Subject. Almost half of the single 
subject studies utilized a combined educational and behavioral treatment technique (n 
= 9, 47.4%). The same number of studies utilized a behavioral approach alone (n = 9, 
47.4%). Only one study (5.3%) used another combination (i.e., behavioral and 
organizational). The length of the treatments ranged from 1 to 112 days (M = 56.9, 
SD = 33.2). 
Non-independent Data. Because studies could focus on more than one aspect 
of a medical regimen (i.e., diet and medication) and could include multiple outcome 
measures, the following data are not independent and were considered as such in 
subsequent analyses. The regimens targeted in the non-single subject studies 
included: medication (n = 32, 46.4%), diet (n = 13, 18.8%), overall disease 
management (n = 10, 14.5%), monitoring (n = 10, 14.5%), and exercise (n = 4, 5.8%). 
Adherence was measured primarily through subjective methods (n = 40, 63.5%). 
These data were obtained through child report (n = 14), parent report (n = 9), diary (n 
= 9), and 24-hour recall (n = 8). Twenty-seven percent of the data (n = 17) were 
derived from indirect measures (electronic monitor, n = 10; pill count, n = 7). The 
remainder of the data was from direct measures (i.e., blood and urine tests; n = 6, 
9.5%).  
Non-independent Data – Single Subject. The regimens targeted by the single 
subject studies included: medication (n = 11, 34.4%), monitoring (n = 9, 28.1%), 
32 
 overall disease management (n = 5, 15.6%), diet (n = 4, 12.5%), and exercise (n = 3, 
9.4%). Adherence data were obtained primarily through diary methods (n = 23, 
71.9%). The remainder of the data was obtained through electronic monitoring (n = 4, 
12.5%), pill count (n = 3, 9.4%), and 24-hour recall (n = 2, 6.3%). 
 Follow-up and Health Outcome Data. Of the included studies, 10 (19.6%) 
included follow-up adherence data. The average length of follow-up was 8 months, 
with a range from 3 to 13 months. Thirty-one studies (60.8%) included health 
outcome data. Most of the health outcome data were direct measures (n = 27, 56.3%), 
which included A1C (n = 15), body mass index (BMI; n = 6), and pulmonary function 
tests (PFT; n = 6). The remainder of the health outcome data included disease activity 
estimates (n = 13, 27.1%), healthcare utilization (n = 4, 8.3%), and quality of life 
measures (n = 4, 8.3%). Of the studies that included health outcome data, 13 provided 
follow-up health outcome data. Length of follow-up ranged from 0.5 to 24 months, 
with a mean of 9.2 months. This follow-up data were derived from A1C (n = 7), BMI 
(n = 3), PFT (n = 4), and disease activity estimates (n = 3). 
 Follow-up and Health Outcome Data – Single Subject. Most of the single 
subject studies (n = 14, 70.0%) included follow-up adherence data. Seven studies 
(35.0%) included health outcome data. The health outcome data included A1C (n = 
3), PFT (n = 3), quality of life (n = 2), BMI (n = 1), and disease activity estimates (n 
= 1). Of the studies that included this data, four provided follow-up health outcome 
data. The follow-up data were derived from A1C (n = 2), PFT (n = 2), and disease 
activity estimates (n = 1). 
33 
 Adherence Outcomes 
 The weighted-mean effect across all of the adherence outcomes was in the 
medium range (Mean d = .58, 95% confidence interval (CI) = 0.51 – 0.65). However, 
there was a significant amount of heterogeneity among the effect sizes (Q = 194.96, 
see Table 3), suggesting that the overall mean effect size combines data that likely do 
not represent the same phenomena. Thus, in order to appropriately interpret these 
data, they should be broken down into meaningful groups so as to attempt to gain 
homogeneity (Durlak, 2003). Weighted mean effect sizes and Q statistics of 
homogeneity are presented for potential moderators in Tables 3, 4, 5, 6, and 7. The Q 
statistic was also used to evaluate between group homogeneity in order to determine 
whether the moderator groups represented statistically significant different effect 
sizes. 
Heterogeneity continues to be a problem in the data, particularly when the data are 
divided by methodological design and diagnostic group. Some homogeneity emerges 
when the effect sizes are divided by intervention type, suggesting that this may be a 
meaningful way to interpret the results. Specifically, the studies using a single 
intervention method had higher mean effect sizes (Educational only: Mean d = .56, 
Behavioral only: Mean d = .51, Organizational only: Mean d = .50) than the studies 
with Combined Educational and Behavioral interventions (Mean d = .36). By this 
grouping, the strongest mean effect sizes were in studies using all other combinations 
(Mean d = .76). However, a follow-up analysis of between group differences was 
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 not significant, suggesting that these differences in mean effect size are not 
statistically significant. 
 Among the studies using a comparison control group methodological design, 
the data exhibited some homogeneity and significant between group differences. 
Specifically, studies using a waitlist design had a significantly stronger mean effect 
size (Mean d = 1.09) than those using an alternative treatment (Mean d = .43) or 
treatment as usual (Mean d = .56). There was also some homogeneity when the data 
were organized by outcome type. The effect sizes were homogeneous within direct 
(i.e., blood/ urine tests) and indirect (i.e., pill count and electronic monitoring) 
measures, but not within the subjective measures (i.e., child and parent report). 
Interestingly, when direct measures are used to measure adherence, the mean effect 
size suggests that adherence interventions are not successful at increasing adherence, 
as indicated by the confidence interval, which includes zero. 
 Heath Outcome Effect Sizes. The weighted-mean effect across all of the health 
outcomes was in the medium range (Mean d = .40, 95% CI = 0.31 – 0.50). However 
there was a significant amount of heterogeneity, suggesting that the overall mean 
effect size is not an appropriate way to represent the average effectiveness of 
adherence interventions on health outcomes. Thus the data were divided into groups 
based on potential moderators. On doing so, several trends emerge. Specifically, 
health outcome measurements from studies using a pre-post design had a stronger 
mean effect size (Mean d = 1.27) than the studies using a comparison group design 
(Mean d = .22). Additionally, positive health outcomes were stronger in studies 
44 
 focused on children with asthma (Mean d = .86) compared to those targeting children 
with Type 1 diabetes (Mean d = .29) or those targeting other diagnoses (Mean d = 
.24). Finally, different than the adherence outcome effect sizes, the health outcome 
data indicated the strongest results from studies using a combination of educational 
and behavioral interventions (Mean d = .74) and single intervention-type studies had 
the weakest results (Mean d = .16). 
 Follow-up Effect Sizes. The weighted-mean effect across all of the follow-up 
adherence data was in the medium range (Mean d = .48, 95% CI = 0.28 – 0.69). 
However, there was a significant amount of heterogeneity, suggesting that the overall 
mean effect size is not an appropriate way to interpret the long term effectiveness of 
adherence interventions. Thus, the data were divided into groups based on potential 
moderators. Overall, there was some homogeneity in these data, but no significant 
between group differences. The best way to understand these data may be to consider 
the regimen component measured. Specifically, the strongest follow-up mean effect 
size was in adherence to diet (Mean d = .86). The next strongest adherence effects 
were in exercise regimens (Mean d = .79) and medication regimens (Mean d = .47). 
The weakest follow-up mean effect size was in overall disease management (Mean d 
= .27). 
 Health Outcome Follow-up Effect Sizes. The weighted-mean effect across all 
of the follow-up health outcome data was in the medium range (Mean d = .36, 95% 
CI = 0.16 – 0.56). However there was a significant amount of heterogeneity, 
suggesting that the overall mean effect size is not an appropriate way to evaluate the 
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 average long term ability of adherence interventions to change health outcomes. 
Thus, the data were divided into groups based on potential moderators. There was 
some homogeneity in all of the different ways the data were grouped. There was both 
homogeneity and between group significant differences when the data were divided 
by diagnostic group, such that health outcome long-term follow-up was not 
significant for Type 1 diabetes (Mean d = .18, 95% CI = -0.06 – 0.42) whereas the 
long term health outcome data were significant and strong for other diagnostic groups 
(Mean d = .73). 
 Single Subject Effect Sizes. The weighted-mean effect across all of the single 
subject adherence data was in the large range (Mean d = 1.53, 95% CI = 1.07 – 1.98). 
This effect size is homogeneous, so it can be considered an appropriate estimate of 
the average effectiveness of single subject adherence interventions. The weighted-
mean effect of the single subject follow-up adherence data was also in the large range 
(Mean d = 1.44, 95% CI = 0.99 – 1.89) and homogeneous. The single subject health 
outcome mean effect was in the large range (Mean d = 0.74, 95% CI = 0.19 – 1.29) 
and homogeneous. The follow-up single subject health outcome mean effect was in 
the large range (Mean d = 0.87, 95% CI = 0.17 – 1.58) and homogeneous. 
 Other Moderating Variables. Correlations were calculated between the effect 
sizes and various potential moderating variables. See Table 8 for a list of all 
correlations. Most of the correlations were not statistically significant. However, the 
percentage of males included in the study was significantly negatively correlated with 
adherence (r2 = -.34) and health outcome (r2 = -.38) effect sizes. In other words, the  
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 Table 8. Correlations between Study Effect Sizes (ES) and Moderating Variables  
Correlated variables r2 Significance 
Overall Adherence Data   
      ES: Mean Age  -.12 t(43) = -0.82 
      ES: Attrition Rate .06 t(33) = 0.34 
      ES: Time since Diagnosis -.09 t(13) = -0.34 
      ES: % of Males -.34 t(35) = -2.12* 
      ES: % of Minority -.14 t(22) = -0.61 
      ES: Length of Treatment -.14 t(46) = -0.97 
   
Follow-up Data   
      ES: Mean Age -.28 t(7) = -0.77 
      ES: Attrition Rate -.32 t(7) = -0.9 
      ES: % of Males -.32 t(6) = -0.83 
      ES: Length of Treatment -.13 t(8) = -0.36 
      ES: Length of Follow-up -.07 t(8) = -0.21 
   
Health Outcome Data   
     ES: Mean Age -.06 t(26) = -0.31 
     ES: Attrition Rate .42 t(23) = 2.13* 
     ES: Time since Diagnosis -.10 t(9) = -0.31 
     ES: % of Males -.38 t(24) = -2.04* 
     ES: % of Minority .06 t(12) = 0.06 
     ES: Length of Treatment -.05 t(28) = -0.26 
   
Health Outcome Follow-up   
     ES: Mean Age -.27 t(10) = -0.90 
     ES: Attrition Rate .24 t(8) = 0.70 
     ES: % of Males -0.56 t(10) = -2.13 
     ES: Length of Treatment -.17 t(10) = -0.17 
     ES: Length of Follow-up .61 t(11) = 0.61 
        
Single Subject Data   
     ES: Mean Age -.15 t(16) = -0.59 
     ES: % of Males -.12 t(17) = -0.51 
     ES: Length of Treatment .36 t(13) = 1.41 
   
Single Subject Follow-up Data   
     ES: Mean Age -.22 t(11) = -0.73 
     ES: Attrition Rate .41 t(12) = 1.54 
     ES: Length of Treatment .71 t(10) = 3.16* 
 *p < .05, **p < .01 
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 more males in the study the less effective the intervention was at increasing 
adherence or improving health outcomes. However, this correlation did not remain 
significant in the follow-up data. Attrition rate was significantly correlated with 
health outcome effect size (r2 = .42), such that the higher the attrition, the better the 
health outcomes. Additionally, the length of treatment was significantly correlated 
with effect size in single subject follow-up data (r2 = .71). So, as the treatment length 
increased, the effectiveness of the intervention at follow-up increased.  
Fail-Safe N-statistic 
 As recommended by Begg (1994), in order to evaluate the possible problem of 
publication bias, Rosenthal’s “file drawer” statistic was calculated (Rosenthal, 1991). 
This statistic provides a number of null result studies that would be needed to make 
the overall weight-mean effect size no longer significant. Rosenthal’s statistic 
suggests that overall mean effect size of this meta-analysis (Mean d = .58, 95% CI = 
0.51 – 0.65) is likely not the result of publication sampling bias, because 245,400 null 
result studies would have to be in “file drawers” to reduce this effect size to a non-
significant result. 
Discussion 
The results of this meta-analysis suggest that adherence interventions not only 
increase adherence, but also generally lead to improved health outcomes, both at the 
completion of the intervention and at follow-up. That is, overall, the effect size 
analyses are very positive and suggest that interventions for children with chronic 
illnesses are generally effective at increasing adherence to treatment regimens. In 
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 fact, the medium level effect sizes are maintained at follow-up. The health outcome 
analyses are also promising. Methodological variables seem to have some effect on 
the effect size estimates of studies. Specifically, effect sizes were significantly higher 
when studies used waitlist control groups, compared to alternative treatments or 
treatment as usual. Additionally, effect sizes differed depending on the outcome 
measured used, such that direct measures of adherence actually showed no significant 
positive effect on adherence and parent reported data showed the most significant 
effects.  
The health outcome analyses revealed some interesting trends. Specifically, 
interventions targeting asthma regimen adherence had significantly better health 
outcomes than those interventions targeting children with type 1 diabetes or other 
diagnoses. Additionally, health outcomes were significantly better when interventions 
used a combined educational and behavioral approach, compared to using a single 
behavioral or educational approach. This finding is particularly interesting because 
the combined educational and behavioral treatments did not appear to be significantly 
different than other techniques at increasing adherence. The follow-up adherence and 
health outcome results are difficult to interpret due to the small number of studies that 
provided this information, which led to low homogeneity and few between group 
differences.  
Most attempts to summarize the information by combining the data into single 
effect size estimates were hampered by significant levels of heterogeneity (except in 
the case of single-subject studies). Heterogeneity persisted even when the effect sizes 
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 were divided in ways that were suggested by previous research to be meaningful. This 
heterogeneity does not indicate that the mean effect size estimates are meaningless, 
but does cast serious doubt on the usefulness of combining all adherence intervention 
research as though it represented a single construct. For example, the tasks required 
for children and families to successfully follow asthma treatment regimens are quite 
different than the tasks required to correctly follow cystic fibrosis treatment regimens. 
Even within the asthma adherence literature, there are differences between the 
structure of interventions necessary to help a family with a preschool aged child with 
asthma and those families with an adolescent with asthma (Graves, Adams, & 
Portnoy, 2006). On the other hand, research in any given area of adherence likely is 
somewhat generalizable. For example, understanding gained about enhancing 
adherence in diabetes can inform research about increasing adherence to post-
transplant medications. However, attempting to evaluate what the important factors 
are in successful adherence interventions by combining all disease types with all 
regimen types and all age groups seems to create too much variance and thus make it 
difficult to come to any useful conclusions.  
 As further illustration of this point, it is noted that there were no problems 
with heterogeneity in the single-subject studies. An examination of the characteristics 
of these studies suggests some possible reasons. First, variance in the type of 
intervention was much smaller in the single-subject designs, because almost half of 
the studies used behavioral techniques alone and almost all of the other studies used 
educational and behavioral techniques combined. In the non-single-subject studies, 
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 although almost half used combined educational and behavioral, the other half 
included a wide range of other techniques. The single-subject studies had a similarly 
lower variance in the kinds of outcome assessment techniques used and the diagnoses 
of the included children. Thus, overall mean effect size estimates appear to be more 
meaningful when there is less variance in the characteristics of the included studies. 
Previous Research 
 Some significant methodological differences exist between this meta-analysis 
and the Kahana et al. (2008) meta-analysis. Kahana et al. (2008) excluded most single 
subject design studies and did not consider health outcome data. By including this 
information into this current meta-analysis, some unique and important information 
was provided about adherence intervention outcomes. Other differences include 
different sampling techniques and exclusion criteria, which created differences in the 
studies that were included in the two meta-analyses. Additionally, in the Kahana et al. 
(2008) meta-analysis some studies contributed more than one effect size to aggregate 
mean effect size. Thus, instead of combining all effect sizes in a study, Kahana et al. 
(2008) opted to separate some outcome statistics in specific circumstances, such as 
when the outcomes measured different adherence constructs (leading to 90 
independent effect sizes, although only 70 studies were included). Despite these 
differences potentially affecting results, the general conclusions are the same. First, 
adherence interventions are generally successful at increasing adherence (overall 
adherence ES for this meta-analysis = 0.58, 95% CI = 0.51 – 0.65; Kahana et al. 
overall adherence ES = 0.34, 95% CI = 0.30–0.38). Second, methodological and 
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 participant characteristics seem to have an effect on intervention effectiveness. Third, 
a significant amount of heterogeneity exists in the data.  
 These general conclusions can also be drawn when comparing this meta-
analysis to those conducted on adult or acutely ill populations. For example, 
combination intervention techniques have strong results in this and other meta-
analyses, especially when compared to single-type interventions (Kahana et al., 2008; 
Roter et al., 1998; Wu & Roberts, 2008). Additionally, direct measures of adherence 
consistently show smaller effect sizes when compared to indirect methods of 
assessment (DiMatteo, 2004; Roter et al., 1998; Wu & Roberts, 2008). Finally, all of 
the meta-analyses that reported heterogeneity statistics also reported that, not only 
was the total effect-size estimate not homogeneous, neither were most of the other 
effect-size estimates (Kahana et al., 2008; Peterson et al., 2003; Wu & Roberts, 
2008).  
Clinical Implications 
By reviewing multiple meta-analyses on similar topics, a pattern begins to 
emerge about adherence interventions. Although the presence of significant 
heterogeneity suggests that conclusions should be drawn cautiously, some clinical 
recommendations can be posited from the areas in which multiple meta-analyses 
seem to agree. First, similar to the conclusions drawn from literature reviews (i.e., 
Rapoff, 1999; Lemanek et al., 2001), the evidence appears to be that adherence 
interventions are most successful when utilizing multiple approaches (e.g., 
educational and organizational, or behavioral and organizational). Additionally, direct 
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 measures of adherence sometimes provide significantly different data than indirect or 
subjective measures. Thus, whenever possible, clinicians should utilize direct 
measures of medication use (e.g., blood titers) to understand a patient’s mediation 
taking behaviors and evaluate the effectiveness of adherence treatment. Finally, since 
participant characteristics (e.g., age, gender, diagnosis) seem to significantly impact 
the effectiveness of adherence interventions overall, it is likely necessary for 
clinicians to considers these characteristics and adapt interventions to meet the 
specific needs of each patient. 
Future Directions 
Based on the results of this meta-analysis, some recommendations can be 
made for future research. First, in order to provide useful information about what 
kinds of adherence interventions are most effective, basic research on adherence 
interventions will need to continue. As the research base grows, then more focused 
meta-analyses can be conducted that evaluate specific areas of adherence 
interventions, such as interventions for adolescents with asthma or school-age 
children with diabetes.  
Second, the ability to summarize and evaluate research would be significantly 
enhanced if important data were uniformly reported in all intervention research, such 
as by using guidelines for the Consolidated Standards of Reporting Trials 
(CONSORT; Moher, Schultz, & Altman, 2001). Fortunately, recent efforts by editors 
to encourage authors to include important methodological and demographic 
information appear to be having positive effects. Specifically, a review of articles in 
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 pediatric and clinic psychology journals published in 2005 compared to 1997, showed 
significant improvement in the reporting of demographic, methodology, and ethical 
details (Raad, Bellinger, McCormick, Roberts, & Steele, 2008). However, progress is 
still needed. For example, in the Journal of Pediatric Psychology, almost 10% of 
articles did not report the gender of their participants and more than 30% did not 
report the SES.  
When considering adherence intervention research, particularly important data 
to report include: demographic information about study participants (i.e., ethnicity, 
SES, gender), information about the medical conditions of study participants (i.e., 
time since diagnosis, severity of disease, comorbid conditions), and intervention or 
treatment variables (i.e., attrition rate, length or intensity of treatment). (See more 
suggestions in Kahana et al., 2008.) Additionally, because the health outcome data 
provided some different results than the adherence data, assessing health outcomes 
appears to be an important way to evaluate the effectiveness of adherence 
interventions and should be included in intervention research. Because different 
results were also obtained depending on the measure of adherence used, researchers 
are encouraged to follow recommendations made previously by Quittner et al. (2000) 
and measure adherence using multiple methods from multiple sources. However, the 
most significant differences in effect sizes appeared in this meta-analysis when direct 
measures of adherence were compared to the effect sizes of all other assessment 
techniques. Thus, efforts should be made to include direct measures, such as blood 
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 medication titers, whenever possible because these data appear to provide unique 
information about adherence (Rapoff, 1999).  
Limitations 
As discussed in length previously, the results of this meta-analysis, especially 
overall effect sizes, should be interpreted with caution due to the high levels of 
heterogeneity in the data. Additionally, because many studies did not include 
information that was used for evaluating the effects of moderators, some of the 
analyses were conducted with only a small percentage of the overall studies. (For 
example, the correlation between study effect size and length of treatment only 
included 13 studies.)  Thus, some of those results may not be accurate reflections of 
the whole field of adherence intervention research. However, this lack of important 
study information was true of most pediatric and child psychology research from the 
time most of these studies were published (mean year of publication = 1996, median 
year of publication = 1999). For example, in a review of all empirical articles 
published in 1997 in four pediatric and child psychology journals, it was discovered 
that 13.8% of the articles did not include gender information and 71.9% not report 
attrition (Sifers, Puddy, Warren, & Roberts, 2002). In the included studies for this 
meta-analysis, 25% did not report gender of participants and 29.4% did not report 
attrition. Finally, it is unclear whether the different methodological decisions made 
for this meta-analysis constitute limitations compared to other adherence intervention 
meta-analyses.  
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 In summary, this meta-analysis provides important information on the current 
state of adherence intervention research. Adherence interventions appear to be 
generally effective. However, adherence intervention research includes such a wide 
variety of chronic conditions, intervention techniques, and other participant variables 
that it is difficult to draw conclusions about the research results as a whole. Instead, 
continued research on focused areas of adherence interventions will likely be the best 
way to understand the most effective ways to help children be more adherent to their 
treatment regimens.  
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Study # ______ 
Coded by: ______ 
Reliability by : ______ 
888 Coded for “other,” 999 Coded for “can’t tell” 
 
Publication’s authors: __________________________________________________ 
 
Type of publication (if two separate reports are being used to code a single study, 
code the more formally published report) 
____ (1) Book 
____ (2) Journal Article  
____ (3) Book Chapter 
____ (4) Thesis or Doctoral    
                  Dissert. 
 
Attrition n = ______, Percent of Original Sample Size_______ 
 
Final Study Sample Size: ______  Treatment Group Sample Size: _____ 
 (participants used in analyses) Control Group Sample Size: _____ 
 
Subject Age:  Mean: ________, Standard Deviation: _______ 
 
Percentage of Minority Participants: _______ 
 
Primary Minority Group Included: 
____ (1) African American 
____ (2) Asian American 
____ (3) Hispanic 
____ (4) Native American 
 
Primary Socioeconomic Status of Population: 
____ (1) Lower Class 
____ (2) Lower Middle Class 
____ (3) Higher Middle Class 
____ (4) Upper Class 
 
Type of assignment to conditions  
____ (1) Random, after matching, stratification, blocking, etc. 
____ (2) Random, simple 
____ (3) Non-random, post-hoc matching 
____ (4) Non-random, other 
If no control group: 
____ (5) Within-subject study design 
____ (6) Single-subject design 
 
Nature of control group 
____ (1) Receives nothing; no evidence of any treatment or attention 
____ (2) Waitlist; delayed treatment 
____ (3) Treatment as usual (typical medical care w/o any extra intervention)  
____ (4) Alternative treatment 
 Diagnosis of Participants 
____ (1) Asthma 
____ (2) Cancer 
____ (3) Cardiovascular     
                   disease 
____ (4) Cerebral Palsy 
____ (5) Cystic Fibrosis 
____ (6) Diabetes – Type 1 
____ (7) Diabetes – Type 2 
____ (8) Epilepsy 
____ (9) Hemophilia 
____ (10) High Blood Pressure 
____ (11) HIV/ AIDS 
____ (12) Hyperlipidemia 
____ (13) Irritable Bowel Diseases 
____ (14) Juvenile Rheumatoid 
Arthritis (JRA) 
____ (15) Renal Diseases 
____ (16) Rheumatic Diseases 
                 (except JRA) 
____ (17) Sickle Cell Disease 
____ (18) Transplant 
 
 
Adherence Outcome Measures 
 
Direct measures 
____ (1) Blood/urine/saliva 
tests for medication presence 
 
Indirect measures 
____ (2) Refill records 
____ (3) Pill count 
____ (4) Mechanical or 
electronic monitors 
Subjective measures 
____ (5) Self-report (parent) 
____ (6) Self-report (child) 
____ (7) Diary/ Record keeping 
____ (8) Physician rating 
____ (9) 24-hour recall (parent) 
____ (10) 24-hour recall (child) 
 
 
Health Outcomes 
 
____ (1) Blood Pressure 
____ (2) Survival 
____ (3) Pain 
____ (4) Incidents of disease flare-up 
____ (5) Weight change  
____ (6) Functional disability 
____ (7) A1C levels  
____ (8) Lung functioning tests (PFT) 
____ (9) Quality of life 
____ (10) Disease severity estimates 
____ (11) Emergency/ Last minute appointments  
____ (12) Appointment keeping 
____ (13) ER visits 
____ (14) Hospitalization 
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 Intervention Strategies (code all that were used in the study) 
Educational strategies 
      Individual 
____ (1) Audiovisual 
____ (2) Computer Programs 
____ (3) Home visits; 
explicitly educational 
____ (4) Mail 
____ (5) Oral 
____ (6) Telephone education 
____ (7) Visual 
____ (8) Written 
____ (9) Modified for 
individual’s specific needs 
     Group Education  
____ (10) Group 
____ (11) Family 
____ (12) Other_____________ 
 
Organizational strategies 
____ (13) Physician education 
____ (14) Physician updated on 
patient 
____ (15) Nurse education 
____ (16) Change to regimen to   
                  reduce barriers (e.g.,      
                  simplification) 
____ (17) Increase accessibility  
                   to health care 
____ (18) Increase consumer 
friendliness 
____ (19) Nurse/ physician   
                  phone contact 
____ (20) Other_____________ 
Behavioral strategies 
____ (21) Calendar 
____ (22) Computerized discharge 
____ (23) Contracting or verbal  
  agreement 
____ (24) Demonstration dose 
____ (25) Family problem-solving  
  training 
____ (26) Feedback 
____ (27) Graphing adherence 
____ (28) Group skill building 
____ (29) Increased parental  
supervision 
____ (30) Medical diaries 
____ (31) Medication monitor 
____ (32) Memory aids  
____ (33) Obtrusive pill count 
____ (34) Pill boxes 
____ (35) Reminder (mail) 
____ (36) Reminder (telephone) 
____ (37) Rewards/ Consequences 
____ (38) Skill building (supervised 
   exercise) 
____ (39) Other________________ 
 
Other/ Affective strategies 
____ (40) Counseling for psych 
d/x’s  (i.e., depression) 
____ (41) Group counseling for 
psych d/x’s  
____ (42) Family support/ therapy  
____ (43) Other________________
 
Intervention Type
____ (1) Education alone 
____ (2) Behavior alone 
____ (3) Affective/ Other alone 
____ (4) Organizational alone 
____ (5) Education and behavior 
____ (6) All other combinations 
 
Length of treatment in days: _____________ 
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 Study # ______ 
Effect size: ______ 
Coded by: ______ 
Reliability by : ______ 
Effect Size #: ______ 
Effect Size Coding 
Use one per effect size coded in each study. For example, two separate pages would 
be used for post-test and 6-month follow-up or for different outcome variables. 
 
Effect Size Type 
____ (1) Post-test Comparison 
____ (2) Follow-up Comparison 
 
Outcome (Compliance) Measure the Effect Size is Based On (use number from above  
list and write a brief descriptor): ____________________________________ 
 
Type of data effect size base on: 
____ (1) Means and SD 
____ (2) t-value or F-value 
____ (3) Chi-square 
____ (4) Frequencies or 
proportions, dichotomous 
 
____ (5) Frequencies or 
proportions, polychotomous 
____ (6) Mean gain scores 
____ (7) Other, specify:_________ 
         
Page number where data for this effect size was found: ________ 
 
Raw difference favors (shows more success for) which group? 
____ (1) Treatment group 
____ (2) Neither (exactly same) 
____ (3) Control group 
 
When means and standard deviations are reported: 
Treatment: 
 Sample Size _______ 
 Mean  _______ 
 Standard Deviation______ 
Control: 
 Sample Size _______ 
 Mean  _______ 
 Standard Deviation______ 
 
When proportions or frequencies are reported: 
 n of treatment group with successful outcome: ___/ total n of trmt group ____ 
 n of control group with successful outcome: ___/ total n of control group ____ 
 
When significance test information is reported: 
 t-value: ______ 
 F-value: ______  df:______ 
 Chi-square value (df = 1): ______ 
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Standardized mean difference ES: 
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Correction for small sample sizes: 
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Weighting ES by inverse variance (sm = standardized mean difference, se = standard 
error): 
                 2 
 2
1
se
w =
 
 
Logit proportion effect size: 
ESl = ln [p/(1-p)]       p = proportion of subjects in category of interest 
       n  = total number of subjects  
 
Standard error for proportions: 
se = √ (1/np) + 1/[n(1-p)]   
Weighting for proportions: 
w = np(1-p) 
 
Random effects variance component: 
 
      where QT is the full group Q statistic, 
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Random-effects weights: 
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Random-effects weighted mean effect size:  Standard error: 
 __                 ________ 
 ES = [∑(w*  x ES)] 2     se =  √(1/ ∑ w*) 
       ∑ w*      
 
Z-test for the Mean ES 
 
 Z = ES / se 
 
95 % confidence interval for Mean ES 
 Lower = ES – 1.96(se) 
 Upper = ES + 1.96(se) 
 
Homogeneity test or Q statistic: 
 
 Q = ∑(w x ES2) –  [∑(w x ES)] 2   
    ∑ w  
 
Comparing two independent groups of effect sizes: 
 
 Within group homogeneity: 
  QW = QGroup_1 + QGroup_2  df = k - j 
   
     where k is the number of effect sizes, and  
      j is the number of groups 
 
 Between group homogeneity: 
  QB = QT  - QW  df = j – 1    where QT is the full group Q statistic 
   
 
If the between groups Q is significant, then the grouping variable accounts for 
significant variability in effect sizes. 
 
Equations taken from “Practical Meta-analysis” by Wilson (2000) 
 
 
